让患者用上更多新药好药

Core Insights - The meeting held in Jiangsu aimed to facilitate communication between key hospitals and pharmaceutical companies to accelerate the implementation of innovative drugs and support high-quality development in the pharmaceutical sector [1] Group 1: Innovative Drug Development - Jiangsu's local pharmaceutical companies have consistently ranked first in the number of innovative drugs included in the national medical insurance directory, with 41 drugs expected to be approved by 2025, accounting for over one-third of the national total [1] - Among these, 21 are significant Class 1 innovative drugs, with 18 being original research drugs developed in Jiangsu, highlighting the province's core competitiveness in pharmaceutical innovation [1] Group 2: Economic Impact - The biopharmaceutical industry in Jiangsu has reached nearly 500 billion yuan in output value, maintaining its position as the leading province in the country [2] - The sales revenue of Zhengda Tianqing Pharmaceutical Group reached 22.5 billion yuan last year, contributing 2.18 billion yuan in taxes to Jiangsu [2] Group 3: Policy Support and Market Access - The Jiangsu government is actively creating platforms for communication to eliminate barriers for innovative drugs entering hospitals, which is crucial for enhancing clinical application [4] - By 2025, it is projected that 399 out of 406 national negotiated drugs will be sold and used in designated medical institutions in Jiangsu, with over 80% of the sales amount coming from these institutions [4] Group 4: Future Initiatives - Jiangsu plans to introduce an artificial intelligence application plan for the biopharmaceutical cluster this year, aiming to cultivate 1-2 industry models and gather typical AI-enabled solutions [7] - The province will also implement a budget policy that allows for separate budgeting for innovative drugs included in the national medical insurance directory, alleviating financial concerns for hospitals [7]